Operaciones Biodesix, Inc. - BDSX CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.0562 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.030779% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | -0.013666% | ||||||||
| Horario tarifa nocturna | 22:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Estadísticas clave
| Cierre previo* | 1.9069 |
| Abrir* | 1.9269 |
| Cambio de 1 año* | -44.63% |
| Rango del día* | 1.837 - 1.9569 |
| Rango de 52 semanas | 0.96-3.87 |
| Volumen medio (10 días) | 141.66K |
| Volumen medio (3 meses) | 4.10M |
| Capitalización de mercado | 138.35M |
| Ratio P/E | -100.00K |
| Acciones en circulación | 71.69M |
| Ingresos | 35.83M |
| EPS | -1.73 |
| Dividendo (Rendimiento %) | N/A |
| Beta | -100.00K |
| Próxima fecha de resultados | Mar 13, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| Feb 8, 2023 | 1.9169 | -0.0299 | -1.54% | 1.9468 | 1.9569 | 1.8370 |
| Feb 7, 2023 | 1.9069 | -0.0300 | -1.55% | 1.9369 | 1.9968 | 1.8370 |
| Feb 6, 2023 | 1.9768 | 0.0499 | 2.59% | 1.9269 | 2.0168 | 1.9269 |
| Feb 3, 2023 | 1.9169 | -0.1498 | -7.25% | 2.0667 | 2.1067 | 1.7871 |
| Feb 2, 2023 | 2.1466 | -0.2296 | -9.66% | 2.3762 | 2.4262 | 2.1266 |
| Feb 1, 2023 | 2.3263 | -0.1099 | -4.51% | 2.4362 | 2.4362 | 2.2663 |
| Jan 31, 2023 | 2.3862 | -0.0399 | -1.64% | 2.4261 | 2.5061 | 2.3262 |
| Jan 30, 2023 | 2.3862 | -0.0299 | -1.24% | 2.4161 | 2.4561 | 2.2663 |
| Jan 27, 2023 | 2.4661 | 0.1598 | 6.93% | 2.3063 | 2.4961 | 2.2963 |
| Jan 26, 2023 | 2.3163 | -0.0200 | -0.86% | 2.3363 | 2.4961 | 2.2763 |
| Jan 25, 2023 | 2.3563 | -0.0399 | -1.67% | 2.3962 | 2.4561 | 2.2663 |
| Jan 24, 2023 | 2.3463 | 0.0200 | 0.86% | 2.3263 | 2.3962 | 2.3063 |
| Jan 23, 2023 | 2.3263 | 0.0100 | 0.43% | 2.3163 | 2.3962 | 2.2264 |
| Jan 20, 2023 | 2.3862 | 0.1498 | 6.70% | 2.2364 | 2.3862 | 2.1965 |
| Jan 19, 2023 | 2.2165 | -0.0199 | -0.89% | 2.2364 | 2.2365 | 2.1765 |
| Jan 18, 2023 | 2.2464 | -0.1697 | -7.02% | 2.4161 | 2.4162 | 2.1665 |
| Jan 17, 2023 | 2.3862 | -0.0799 | -3.24% | 2.4661 | 2.4861 | 2.3462 |
| Jan 13, 2023 | 2.4761 | 0.1498 | 6.44% | 2.3263 | 2.4861 | 2.2464 |
| Jan 12, 2023 | 2.4661 | 0.0599 | 2.49% | 2.4062 | 2.4661 | 2.3262 |
| Jan 11, 2023 | 2.3862 | -0.0100 | -0.42% | 2.3962 | 2.4561 | 2.2464 |
Biodesix, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Anual
- Trimestral
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Ingresos totales | 20.432 | 24.552 | 45.557 | 54.506 |
| Ingresos | 20.432 | 24.552 | 45.557 | 54.506 |
| Coste de los ingresos, total | 4.406 | 6.074 | 21.998 | 30.518 |
| Beneficio bruto | 16.026 | 18.478 | 23.559 | 23.988 |
| Gastos totales de explotación | 44.095 | 51.293 | 68.491 | 93.148 |
| Gastos de venta/general/administración Gastos, total | 25.899 | 30.637 | 32.328 | 47.958 |
| Investigación y desarrollo | 8.188 | 10.468 | 10.818 | 12.789 |
| Gastos (ingresos) extraordinarios | 5.602 | 4.114 | 0.818 | -0.676 |
| Ingresos de explotación | -23.663 | -26.741 | -22.934 | -38.642 |
| Ingresos por intereses (gastos), netos No operativos | -2.892 | -2.953 | -7.586 | -4.508 |
| Otros, netos | 0.389 | -1.032 | -0.83 | -0.009 |
| Ingresos netos antes de impuestos | -26.166 | -30.726 | -31.35 | -43.159 |
| Ingresos netos después de impuestos | -26.166 | -30.726 | -31.35 | -43.159 |
| Beneficio neto antes de partidas extra. Elementos | -26.166 | -30.726 | -31.35 | -43.159 |
| Ingresos netos | -26.166 | -30.726 | -31.35 | -43.159 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -26.166 | -30.726 | -31.35 | -43.159 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -26.166 | -30.726 | -31.35 | -43.159 |
| Beneficio neto diluido | -26.166 | -30.726 | -31.35 | -43.159 |
| Promedio ponderado de acciones diluidas | 26.2541 | 26.2541 | 26.5615 | 27.365 |
| BPA diluido sin partidas extraordinarias | -0.99665 | -1.17033 | -1.18028 | -1.57716 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
| BPA normalizado diluido | -0.78327 | -1.01363 | -1.14948 | -1.60186 |
| Depreciation / Amortization | 2.529 | 2.559 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Ingresos totales | 28.866 | 11.885 | 6.531 | 7.224 | 6.548 |
| Ingresos | 28.866 | 11.885 | 6.531 | 7.224 | 6.548 |
| Coste de los ingresos, total | 18.218 | 7.085 | 2.722 | 2.493 | 3.235 |
| Beneficio bruto | 10.648 | 4.8 | 3.809 | 4.731 | 3.313 |
| Gastos totales de explotación | 35.177 | 22.472 | 16.499 | 19 | 21.009 |
| Gastos de venta/general/administración Gastos, total | 11.927 | 11.425 | 13.607 | 13.558 | 14.487 |
| Investigación y desarrollo | 3.321 | 3.323 | 3.293 | 2.852 | 3.206 |
| Gastos (ingresos) extraordinarios | 1.711 | 0.639 | -3.123 | 0.097 | 0.081 |
| Ingresos de explotación | -6.311 | -10.587 | -9.968 | -11.776 | -14.461 |
| Ingresos por intereses (gastos), netos No operativos | -0.651 | -0.815 | -1.546 | -1.496 | -1.137 |
| Otros, netos | 0.001 | 0 | 0 | -0.01 | 0.012 |
| Ingresos netos antes de impuestos | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
| Ingresos netos después de impuestos | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
| Beneficio neto antes de partidas extra. Elementos | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
| Ingresos netos | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
| Beneficio neto diluido | -6.961 | -11.402 | -11.514 | -13.282 | -15.586 |
| Promedio ponderado de acciones diluidas | 26.604 | 27.73 | 28.051 | 27.059 | 31.07 |
| BPA diluido sin partidas extraordinarias | -0.26165 | -0.41118 | -0.41047 | -0.49085 | -0.50164 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA normalizado diluido | -0.19734 | -0.38814 | -0.5218 | -0.48727 | -0.49903 |
- Anual
- Trimestral
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Total Activo Corriente | 9.913 | 12.7 | 86.14 | 43.613 |
| Efectivo e inversiones a corto plazo | 5.914 | 5.286 | 62.126 | 32.712 |
| Efectivo y Equivalentes | 5.914 | 5.286 | 62.126 | 32.712 |
| Total deudores, neto | 1.892 | 5.292 | 15.304 | 3.656 |
| Accounts Receivable - Trade, Net | 1.892 | 5.292 | 15.304 | 3.656 |
| Other Current Assets, Total | 2.107 | 2.122 | 8.71 | 7.245 |
| Total Assets | 39.057 | 41.633 | 121.07 | 76.097 |
| Property/Plant/Equipment, Total - Net | 1.388 | 2.12 | 3.178 | 4.179 |
| Property/Plant/Equipment, Total - Gross | 6.956 | 8.506 | 9.902 | 10.928 |
| Accumulated Depreciation, Total | -5.568 | -6.386 | -6.724 | -6.749 |
| Goodwill, Net | 10.804 | 11.631 | 15.031 | 15.031 |
| Intangibles, Net | 16.852 | 15.092 | 13.26 | 11.617 |
| Other Long Term Assets, Total | 0.1 | 0.09 | 3.461 | 1.657 |
| Total Current Liabilities | 4.468 | 22.6 | 32.125 | 28.96 |
| Accounts Payable | 0.886 | 1.717 | 8.964 | 1.662 |
| Accrued Expenses | 1.568 | 1.899 | 4.69 | 4.899 |
| Notes Payable/Short Term Debt | 0 | 12.045 | 0 | 0 |
| Other Current Liabilities, Total | 2.014 | 6.939 | 6.631 | 22.38 |
| Total Liabilities | 53.125 | 76.213 | 79.904 | 56.37 |
| Total Long Term Debt | 23.099 | 23.812 | 15.926 | 9.993 |
| Long Term Debt | 23.099 | 23.812 | 15.926 | 9.993 |
| Other Liabilities, Total | 25.558 | 29.801 | 31.853 | 17.417 |
| Total Equity | -14.068 | -34.58 | 41.166 | 19.727 |
| Redeemable Preferred Stock | 183.962 | 193.959 | 0 | 0 |
| Common Stock | 0.001 | 0.001 | 0.027 | 0.031 |
| Additional Paid-In Capital | 2.107 | 2.324 | 299.953 | 321.669 |
| Retained Earnings (Accumulated Deficit) | -200.138 | -230.864 | -258.814 | -301.973 |
| Total Liabilities & Shareholders’ Equity | 39.057 | 41.633 | 121.07 | 76.097 |
| Total Common Shares Outstanding | 26.2541 | 26.2541 | 26.5615 | 30.7896 |
| Current Port. of LT Debt/Capital Leases | 0 | 11.84 | 0.019 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 81.244 | 68.45 | 56.445 | 43.613 | 27.233 |
| Efectivo e inversiones a corto plazo | 55.329 | 56.349 | 47.913 | 32.712 | 16.427 |
| Efectivo y Equivalentes | 55.329 | 56.349 | 47.913 | 32.712 | 16.427 |
| Total deudores, neto | 18.367 | 5.281 | 2.784 | 3.656 | 3.774 |
| Accounts Receivable - Trade, Net | 18.367 | 5.281 | 2.784 | 3.656 | 3.774 |
| Other Current Assets, Total | 7.548 | 6.82 | 5.748 | 7.245 | 7.032 |
| Total Assets | 115.486 | 101.804 | 89.997 | 76.097 | 61.651 |
| Property/Plant/Equipment, Total - Net | 3.387 | 3.378 | 4.432 | 4.179 | 6.247 |
| Property/Plant/Equipment, Total - Gross | 10.369 | 10.471 | 11.827 | 10.928 | 13.409 |
| Accumulated Depreciation, Total | -6.982 | -7.093 | -7.395 | -6.749 | -7.162 |
| Goodwill, Net | 15.031 | 15.031 | 15.031 | 15.031 | 15.031 |
| Intangibles, Net | 12.821 | 12.4 | 11.992 | 11.617 | 11.131 |
| Other Long Term Assets, Total | 3.003 | 2.545 | 2.097 | 1.657 | 2.009 |
| Total Current Liabilities | 16.124 | 21.272 | 22.787 | 28.96 | 29.811 |
| Accounts Payable | 3.747 | 1.16 | 1.6 | 1.662 | 2.12 |
| Accrued Expenses | 2.622 | 2.959 | 3.533 | 4.899 | 4.597 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 2.707 | 3.106 | 0.02 | 0.019 | 0.051 |
| Other Current Liabilities, Total | 7.048 | 14.047 | 17.634 | 22.38 | 23.043 |
| Total Liabilities | 79.054 | 76.031 | 73.964 | 56.37 | 53.87 |
| Total Long Term Debt | 30.328 | 29.955 | 29.975 | 9.993 | 10.055 |
| Long Term Debt | 30.328 | 29.955 | 29.975 | 9.993 | 10.055 |
| Other Liabilities, Total | 32.602 | 24.804 | 21.202 | 17.417 | 14.004 |
| Total Equity | 36.432 | 25.773 | 16.033 | 19.727 | 7.781 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Common Stock | 0.027 | 0.027 | 0.027 | 0.031 | 0.032 |
| Additional Paid-In Capital | 302.18 | 302.923 | 304.697 | 321.669 | 325.308 |
| Retained Earnings (Accumulated Deficit) | -265.775 | -277.177 | -288.691 | -301.973 | -317.559 |
| Total Liabilities & Shareholders’ Equity | 115.486 | 101.804 | 89.997 | 76.097 | 61.651 |
| Total Common Shares Outstanding | 26.7854 | 26.9489 | 27.0201 | 30.7896 | 31.8893 |
- Anual
- Trimestral
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Ingresos netos/Línea de salida | -26.166 | -30.726 | -31.35 | -43.159 |
| Efectivo de actividades de explotación | -17.677 | -21.726 | -21.366 | -28.223 |
| Efectivo de actividades de explotación | 1.74 | 2.793 | 2.903 | 3.178 |
| Partidas no monetarias | 6.496 | 7.852 | 11.882 | 7.167 |
| Cambios en el capital circulante | 0.253 | -1.645 | -4.801 | 4.591 |
| Efectivo de actividades de inversión | -0.617 | -1.872 | -2.927 | -2.547 |
| Gastos de capital | -0.617 | -1.416 | -2.177 | -2.547 |
| Otras partidas de flujo de caja de inversión, total | 0 | -0.456 | -0.75 | 0 |
| Efectivo procedente de actividades de financiación | 19.032 | 22.972 | 81.131 | 1.262 |
| Elementos de flujo de caja de financiación | -0.283 | -0.119 | -8.249 | -0.5 |
| Emisión (retiro) de acciones, neto | 8.55 | 10.047 | 73.34 | 17.112 |
| Emisión (amortización) de deuda, neta | 10.765 | 13.044 | 16.04 | -15.35 |
| Variación neta de la tesorería | 0.738 | -0.626 | 56.838 | -29.508 |
| Intereses pagados en efectivo | 1.844 | 1.676 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -6.961 | -18.363 | -29.877 | -43.159 | -15.586 |
| Cash From Operating Activities | -11.326 | -10.236 | -18.026 | -28.223 | -13.099 |
| Cash From Operating Activities | 0.746 | 1.523 | 2.323 | 3.178 | 0.908 |
| Non-Cash Items | 3.721 | 5.336 | 4.704 | 7.167 | 2.674 |
| Changes in Working Capital | -8.832 | 1.268 | 4.824 | 4.591 | -1.095 |
| Cash From Investing Activities | -0.516 | -0.864 | -1.906 | -2.547 | -0.352 |
| Capital Expenditures | -0.516 | -0.864 | -1.906 | -2.547 | -0.352 |
| Other Investing Cash Flow Items, Total | 0 | 0 | 0 | 0 | |
| Cash From Financing Activities | 4.951 | 5.229 | 5.625 | 1.262 | -2.834 |
| Financing Cash Flow Items | -0.108 | -0.109 | 0.232 | -0.5 | -4.6 |
| Issuance (Retirement) of Stock, Net | 0.475 | 0.679 | 0.739 | 17.112 | 1.674 |
| Issuance (Retirement) of Debt, Net | 4.584 | 4.659 | 4.654 | -15.35 | 0.092 |
| Net Change in Cash | -6.891 | -5.871 | -14.307 | -29.508 | -16.285 |
| Cash Interest Paid | 0.223 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| Schuler (Jack W) | Individual Investor | 27.8328 | 19952112 | 8695652 | 2022-11-21 | LOW |
| Kennedy (Lawrence T Jr.) | Individual Investor | 20.684 | 14827404 | 0 | 2023-01-03 | MED |
| Patience (John) | Individual Investor | 9.7923 | 7019695 | 1739130 | 2022-11-21 | LOW |
| Birchview Capital, LP | Investment Advisor | 7.0302 | 5039633 | 2884624 | 2022-12-31 | LOW |
| Cawthorn (Robert E) | Individual Investor | 5.0948 | 3652220 | 1723341 | 2022-11-21 | LOW |
| Strobeck (Matthew W) | Individual Investor | 4.052 | 2904668 | 1304345 | 2022-11-21 | LOW |
| Industrial Development Funding LLC | Corporation | 2.6454 | 1896374 | 0 | 2022-03-01 | LOW |
| Wells Fargo Advisors | Research Firm | 1.0724 | 768725 | 221413 | 2022-09-30 | LOW |
| Essex Investment Management Company, LLC | Investment Advisor/Hedge Fund | 0.5273 | 377994 | -29 | 2022-12-31 | LOW |
| Life Sciences Alternative Financing, L.L.C. | Corporation | 0.4102 | 294053 | 0 | 2022-03-01 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.3343 | 239656 | 59660 | 2022-09-30 | LOW |
| Cannell & Co. | Investment Advisor | 0.2868 | 205605 | 0 | 2022-12-31 | LOW |
| Hutton Scott | Individual Investor | 0.2389 | 171227 | 96218 | 2022-11-21 | LOW |
| Massarany (Hany) | Individual Investor | 0.1924 | 137934 | 130434 | 2022-11-21 | HIGH |
| Endurant Capital Management LP | Hedge Fund | 0.1815 | 130136 | -617 | 2022-09-30 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.1731 | 124070 | 27282 | 2022-09-30 | LOW |
| Millennium Management LLC | Hedge Fund | 0.1647 | 118048 | 728 | 2022-09-30 | HIGH |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.1395 | 100000 | 50000 | 2022-09-30 | LOW |
| Pestano (Gary Anthony) | Individual Investor | 0.1294 | 92732 | 3474 | 2022-11-10 | |
| Cowie (Robin Harper) | Individual Investor | 0.1282 | 91920 | 25383 | 2022-11-21 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group +500000+
Traders
93000+
Clientes activos mensualmente
$57000000+
Volumen mensual de inversión
$31000000+
Pruébalo ahora Retiros por mes
Calculadora de trading
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Comisión de la operación
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Apalancamiento
20:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Biodesix, Inc. Company profile
Sobre Biodesix Inc
Biodesix, Inc. es una empresa con sede en Estados Unidos que se dedica a desarrollar y comercializar pruebas de diagnóstico en sangre para oncología. Su producto Biodesix Lung Reflex integra resultados genómicos y proteómicos en sangre para revelar las dos caras del cáncer de pulmón. Su prueba GeneStrat ofrece resultados de mutaciones en sangre en un plazo de 72 horas para pacientes con cáncer de pulmón de células no pequeñas (CPCNP). Su prueba VeriStrat ofrece información proteómica predictiva y pronóstica basada en la sangre con (CPNM) que dan negativo en las pruebas de mutaciones de la tasa de filtración glomerular estimada (EGFR wild-type) o cuyo estado de mutación del EGFR se desconoce.
| Industry: | Medical & Diagnostic Laboratories |
Suite 100
2970 Wilderness Place
BOULDER
COLORADO 80301
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com